关键词： Foresite 基因组学 诊断学
2013年2月2日讯 /生物谷BIOON/ --位于San Francisco的风投公司Foresite宣布将投资一亿美元用于支持相关生物技术公司在基因组学和诊断学方面的研究。Foresite这次投资的目标包括了AcelRx , Keryx and Puma Biotechnology .和 Jim Tananbaum等生物技术公司。
最近几年，风投公司将大笔资金投入到研发的后期阶段中，与之形成鲜明对比的是研究人员一直苦于很难获得充足的启动资金来开始自己的研究。（生物谷Bioon.com）
详细英文报道：
Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.
Foresite's release spotlights a slate of biotech investments in the portfolio, including AcelRx ($ACRX), Keryx ($KERX) and Puma Biotechnology ($PBYI). And Jim Tananbaum, founder and managing director of Foresite Capital Management, says he's eager to jump into other companies that are going places.
"We are marrying the best practices of growth investing with healthcare specialization," Tananbaum announced in a statement. "We are proud of our capital base, extremely excited about the prospects for healthcare growth, and believe on a risk-adjusted basis there has never been a better time to have this focus."
In recent years a number of biotech venture groups have steered new funds toward late-stage assets, looking to improve their shot at a relatively quick return in an industry which can be notoriously slow and risky when it comes to new product development. But with players crowding one end of the field, startups have complained that getting enough cash to make it through the early-stage valley of death is tougher than ever.
